Top biotech investor Peter Kolchinsky tees up a new SPAC — 3 days after a $300M raise for radiopharmaceuticals play
Three days after RA Capital founder Peter Kolchinsky steered his first SPAC into a $300 million raise for Point Biopharma’s late-stage radiopharmaceuticals play, he’s teed up a new one.
As with all blank check plays, the details are all bare bones right now. Kolchinsky raised $130 million after pricing at $10 a share — with a $30 million add-on — for this new SPAC, dubbed Research Alliance II. And that will set up a substantial reverse raise for a biotech looking to go public.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 105,400+ biopharma pros reading Endpoints daily — and it's free.